Last checked at 7 Apr 2016 11:41
Hikma Pharmaceuticals PLC
Annual Information Update
London, 7 April 2016. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to in this update was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Date | Headline |
07/04/2016 | Annual Financial Report |
06/04/2016 | Blocklisting Interim Review |
05/04/2016 | Director/PDMR Shareholding |
31/03/2016 | Director/PDMR Shareholding |
29/03/2016 | Director/PDMR Shareholding |
21/03/2016 | Director/PDMR Shareholding |
17/03/2016 | Director/PDMR Shareholding |
16/03/2016 | Final Results |
03/03/2016 | Notice of Results |
29/02/2016 | Holding(s) in Company |
29/02/2016 | Holding(s) in Company |
29/02/2016 | Total Voting Rights |
29/02/2016 | Roxane Acquisition Close |
22/02/2016 | Directorate Change |
19/02/2016 | EGM Statement |
11/02/2016 | Holding(s) in Company |
11/02/2016 | Circ re. Roxane Acquisition |
10/02/2016 | Circ re. Roxane Acquisition |
22/01/2016 | Circ re. Roxane Acquisition and EGM |
07/01/2016 | Total Voting Rights |
24/12/2015 | Shareholders' Agreement and Board Appointment |
17/12/2015 | Total Voting Rights |
03/12/2015 | Director/PDMR Shareholding |
25/11/2015 | Hikma announces sale of Ben Venue manufacturing |
24/11/2015 | Holding(s) in Company |
18/11/2015 | Resolution to FDA Warning Letter |
16/11/2015 | Holding(s) in Company |
11/11/2015 | Holding(s) in Company |
10/11/2015 | Holding(s) in Company |
02/11/2015 | Trading Statement |
22/10/2015 | Block Listing of Share |
19/10/2015 | Holding(s) in Company |
12/10/2015 | Blocklisting Interim Review |
08/10/2015 | Total Voting Rights |
18/09/2015 | Audit Tender |
16/09/2015 | Total Voting Rights |
11/09/2015 | Director/PDMR Shareholding |
27/08/2015 | Director/PDMR Shareholding |
27/08/2015 | Director/PDMR Shareholding |
19/08/2015 | Director/PDMR Shareholding |
19/08/2015 | Interim Results |
28/07/2015 | Acquisition |
14/07/2015 | Total Voting Rights |
18/05/2015 | Director/PDMR Shareholding |
15/05/2015 | Director/PDMR Shareholding |
14/05/2015 | Result of AGM |
14/05/2015 | AGM Trading Update |
15/04/2015 | Holding(s) in Company |
10/04/2015 | Total Voting Rights |
10/04/2015 | Director/PDMR Shareholding |
09/04/2015 | Annual Information Update |
All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com).
Documents filed with the Financial Conduct Authority
The Company has filed the following documents with the Financial Conduct Authority ("FCA") via the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.
Date | Document |
07/04/2016 | Annual Report and Accounts 2015 |
07/04/2016 | Notice of 2016 Annual General Meeting |
07/04/2016 | Proxy form for the 2016 Annual General Meeting |
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.
Date Filed | Form | Description |
02/03/2016 | AP01 | Appointment of John Julius Castellani as a director on 1 March 2016 |
29/02/2016 | SH01 | Statement of capital following an allotment of shares on 29 February 2016 |
29/02/2016 | AP01 | Appointment of Jochen Gann as a director on 29 February 2016 |
07/01/2016 | SH01 | Statement of capital following an allotment of shares on 7 January 2016 |
17/12/2015 | SH01 | Statement of capital following an allotment of shares on 16 December 2015 |
09/10/2015 | SH01 | Statement of capital following an allotment of shares on 9 October 2015 |
17/09/2015 | SH01 | Statement of capital following an allotment of shares on 17 September 2015 |
11/09/2015 | AR01 | Annual return made up to 7 September 2015 no member list |
09/09/2015 | SH01 | Statement of capital following an allotment of shares on 19 August 2015 |
15/07/2015 | SH01 | Statement of capital following an allotment of shares on 13 July 2015 |
10/06/2015 | AA | Group of companies' accounts made up to 31 December 2014 |
29/05/2015 | RESOLUTIONS | RES09 - Resolution of authority to purchase a number of sharesRES10 - Resolution of allotment of securitiesRES10 - Resolution of allotment of securities |
07/04/2015 | SH01 | Statement of capital following an allotment of shares on 31 March 2015 |
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk.
Documents provided to Shareholders
Further Information
Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.
Peter Speirs
Company Secretary7 April 2016
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.